

Amendments to the Claims

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (previously presented) A method comprising transplantation of insulin producing cells in the form of isolating islets to a patient suffering from insulin dependent diabetes mellitus (IDDM),

wherein said isolated islets are modified by irreversible adsorption with a clotting preventing agent,

with the proviso that the isolated islets are not artificially encapsulated,

whereby said clotting preventing agent acts to prevent or reduce clotting.

2. (previously presented) The method according to claim 1, wherein the preventing agent is an anticoagulant.

3. (previously presented) The method according to claim 2, wherein the anticoagulant is heparin or fractions or derivatives thereof.

4. (currently amended) ~~The method according to claim 3~~ A method comprising transplantation of insulin

producing cells in the form of isolating islets to a patient
suffering from insulin dependent diabetes mellitus (IDDM),
wherein said isolated islets are modified by
irreversible adsorption with heparin or a fraction or
derivative thereof,

wherein said islet cells are coated with heparin or
a fraction ~~fractions or derivatives~~ derivative thereof by
preincubation of islets in a solution containing heparin or
~~fractions~~ a fraction or ~~derivatives~~ derivative thereof,
wherein said anticoagulant acts to prevent clotting
or reduce clotting.

5. (previously presented) The method according to
claim 1, wherein the preventing agent is an inhibitor of
platelet activation.

6. (previously presented) The method according to
claim 5, wherein the preventing agent is a RGD containing
peptide or a monoclonal antibody which inhibits the
interaction of platelet integrins with their specific ligands.

7. (previously presented) The method according to
claim 5, wherein the preventing agent is a monoclonal antibody
or a peptide directed against the Fc receptor on platelets.

8. (previously presented) The method according to any one of the claims 1-7, wherein more than one clotting preventing agent is used.

9. (previously presented) The method according to any one of the claims 1-7, wherein the preventing agent is supplemented by an inhibitor of complement.

10. (previously presented) A method for coating isolated cells, comprising

coating islets of Langerhans cells with a heparin conjugate on the islet surface, with the proviso that the cells are not artificially encapsulated,

whereby clotting is reduced or prevented.

11. (previously presented) A method for increasing survival of islet cells in connection with transplantation of insulin producing cells to patients with insulin dependent diabetes mellitus (IDDM), comprising prevention of clotting, monitored as reduced generation of thrombin-antithrombin complex (TAT complex).

12. (previously presented) The method of claim 1, with the proviso that the isolated islets are not encapsulated with an organic material comprising hollow bodies.

13. (previously presented) The method of claim 1, wherein said isolated islets are modified with said clotting preventing agent by bringing soluble Heparin in contact with said isolated islets, or by mixing a Heparin conjugate with said islets.